Advanced search
Publication Cover
Journal of Medical Economics Volume 23, 2020 - Issue 2
Submit an article Journal homepage
3,107
Views
1
CrossRef citations to date
0
Altmetric
Oncology

Real-world treatment patterns, cost of care and effectiveness of therapies for patients with squamous cell carcinoma of head and neck pre and post approval of immuno-oncology agents

Pranav AbrahamBristol-Myers Squibb, Lawrence Township, NJ, USA; Correspondence[email protected]
,
Jonathan Karl KishCardinal Health, Dublin, OH, USA;
,
Beata KorytowskyBristol-Myers Squibb, Lawrence Township, NJ, USA;
,
Janna RadtchenkoFormerly of Cardinal Health, Dublin, OH, USA
,
Prianka SinghBristol-Myers Squibb, Lawrence Township, NJ, USA;
,
James ShawBristol-Myers Squibb, Lawrence Township, NJ, USA;
&
Bruce FeinbergCardinal Health, Dublin, OH, USA;
show all
Pages 125-131 | Received 19 Jun 2019, Accepted 07 Sep 2019, Published online: 18 Oct 2019

References

  • Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA. 2018;68(1):7–30.
  • Noone AH, Krapcho M, Miller D, et al. (eds). SEER cancer statistics review, 1975–2015, Bethesda, MD: National Cancer Institute. https://seer.cancer.gov/csr/1975_2015/.
  • Marur S, Forastiere AA. Head and neck squamous cell carcinoma: update on epidemiology, diagnosis, and treatment. Mayo Clinic Proc. 2016;91(3):386–396.
  • Natonal Cancer Institute. FDA approves nivolumab for head and neck cancer. Available from: https://www.cancer.gov/news-events/cancer-currents-blog/2016/fda-nivolumab-scchn. 2016.
  • National Cancer Institute. FDA approves pembrolizumab for head and neck cancer. Available from: https://www.cancer.gov/news-events/cancer-currents-blog/2016/fda-pembrolizumab-hnscc 2016.
  • Ferris RL, Blumenschein G, Jr., Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856–1867.
  • Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016;17(7):956–965.
  • Cohen E, Harrington K, Le Tourneau C, et al. Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): phase 3 KEYNOTE-040 trial. Oral presentation at ESMO 11 September 2017. 2017; Abstract LBA45.
  • Cohen EEW, Soulieres D, Le Tourneau C, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet (London, England). 2019;393(10167):156–167.
  • Ward MC, Shah C, Adelstein DJ, et al. Cost-effectiveness of nivolumab for recurrent or metastatic head and neck cancer. Oral Oncol. 2017;74:49–55.
  • Zargar M, McFarlane T, Chan KKW, et al. Cost-effectiveness of nivolumab in recurrent metastatic head and neck squamous cell carcinoma. Oncologist. 2018;23(2):225–233.
  • Tringale KR, Carroll KT, Zakeri K, et al. Cost-effectiveness analysis of nivolumab for treatment of platinum-resistant recurrent or metastatic squamous cell carcinoma of the head and neck. J Natl Cancer Inst. 2018;110(5):479–485.
  • Hirschmann A, Lupatsch JE, Schwenkglenks M, et al. Cost-effectiveness of nivolumab in the treatment of head and neck cancer. Oral Oncol. 2018;87:104–110.
  • Verma V, Sprave T, Haque W, et al. A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors. J Immunother Cancer. 2018;6(1):128.
  • Ricketts K, Williams M, Liu ZW, et al. Automated estimation of disease recurrence in head and neck cancer using routine healthcare data. Comput Methods Programs Biomed. 2014;117(3):412–424.
  • Korytowsky B, Radtchenko J, Abraham P, et al. Validation of a claims-based algorithm for identification of patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) in the US. Value Health. 2018;21:S218.
  • Reveles IAR, KR, Frei BL, Frei CR, et al. Cost of squamous cell cancer of the head and neck. AJPB. 2017;9(3):89–94.
  • Wissinger E, Griebsch I, Lungershausen J, et al. The economic burden of head and neck cancer: a systematic literature review. Pharmacoeconomics. 2014;32(9):865–882.
  • Hollenbeak CS, Kulaylat AN, Mackley H, et al. Determinants of medicare costs for elderly patients with oral cavity and pharyngeal cancers. JAMA Otolaryngol Head Neck Surg. 2015;141(7):628–635.
  • Jacobson JJ, Epstein JB, Eichmiller FC, et al. The cost burden of oral, oral pharyngeal, and salivary gland cancers in three groups: commercial insurance, Medicare, and Medicaid. Head Neck Oncol. 2012;4:15.
  • Fisher MD, Fernandes AW, Olufade TO, et al. Patient characteristics and costs in recurrent or refractory head and neck cancer: retrospective analysis of a community oncology database. Clin Ther. 2018;40(4):562–573.
  • Kemp R, Prasad V. Surrogate endpoints in oncnology: when are they acceptable for regulatory and clinical decisions, and are they currenlty used? BMC Med. 2017;15(1):134.
  • Bognar K, Romley JA, Bae JP, et al. The role of imperfect surrogate endpoint information in drug approval and reimbursement decisions. J Health Econ. 2017;51:1–12.
  • Fisher MD, Fernandes AW, Olufade TO, et al. Effectiveness outcomes in patients with recurrent or refractory head and neck cancers: retrospective analysis of data from a community oncology database. Clin Ther. 2018;40(9):1522–1537.
  • Wissinger E, Griebsch I, Lungershausen J, et al. The humanistic burden of head and neck cancer: a systematic literature review. Pharmacoeconomics. 2014;32(12):1213–1229.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.